Please enable JavaScript or talk to your local administrator to get JavaScript enabled.
Skip filters
Skip facets
Funder
  • 110

  • 23

  • 16

  • 14

  • 12

  • 11

  • 8

  • 7

  • 6

  • 6

Funder Group
Research Organization
FOR (ANZSRC) Category
RCDC Category
Researcher
City
State
Country
Country of Funder
Start Year
Active Year
Similar Projects for

Project

Identifying Immunological Basis for Bladder Cancer Sex Bias

Funder: Canadian Institutes of Health Research

Funding period
CAD 35 K
USD 26 K
Funding amount
Abstract
Bladder cancer incidence shows an enigmatic male bias, as it is the 4th most common cancer in men but only the 12th most common cancer in women in Canada. The bias cannot be fully accounted for by lifestyle factors such as smoking, suggesting that it is likely a consequence of more fundamental biological differences between two sexes. To this end, we analyzed human primary bladder cancers and discovered that immune pathways are more enriched in women than in men, which hinted that sex bias may be driven by sex-specific differences in immune function. To address this possibility, we utilized the preclinical murine bladder cancer models that recapitulate the male bias seen in human bladder cancer. Remarkably, we observed that hormonally mediated differences in T cell immunity are responsible for sexual dimorphism in tumor growth. Our Research Proposal seeks to determine exact mechanisms by which sex hormones regulate T cell immunity. Male-based studies predominate in immunology research despite clear evidence that sex discrepancy exists in the outcome from many infectious and autoimmune diseases, vaccines and malignancies. Erroneous assumption that such results can be generalized to both sexes not only damages the scientific rigor and reproducibility but is also a major barrier to the long-term goal of personalizing treatments for immune-related diseases. Specific study design in our Proposal, explicitly aiming to highlight the immune mechanisms underlying unique protection against bladder cancer in females, presents an innovative approach to identify novel therapeutic targets. Also, completion of proposed research will establish an important insight that anti-tumor immunity may be largely different between men and women, thereby emphasizing sex as a critical biological variable to consider in designing future pre-clinical/clinical immunotherapy studies.

 
270
Projects
USD 173.2 M
Aggregated funding amount
USD 687 K
Average funding amount
Project list item
Recombinant CCL2 as a novel treatment strategy for bladder cancer

Bladder Cancer Advocacy Network to Neelam Mukherjee, Robert Scott Svatek

USD 50,000
2019 - 2020
Project list item
Biomarker-Based Tools for Treatment Response Decision Support of Bladder Cancer

National Cancer Institute to LUBOMIR M HADJIYSKI, AJJAI SHIVARAM ALVA

USD 653,319
2019 - 2024
Project list item
Refined phenotyping and personalized targeting of muscle-invasive bladder cancer

Swiss National Science Foundation to Roland Seiler, Vera Genitsch, Kiu Yan Charlotte Ng, Marianna Kruithof-de Julio, Franziska Singer

USD 702,564
2019 - 2023
Project list item
Chromatin Modifier Gene Mutation and Enhancer Dysfunction in Bladder Cancer

National Cancer Institute to BYRON H LEE

USD 243,205
2019 - 2024
Project list item
Combatting Bladder Cancer by Inducing Epithelial Turnover

National Cancer Institute to SOMAN N ABRAHAM

USD 203,510
2019 - 2021
Project list item
Phase 1/2 Study of Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder - (ADAPT-BLADDER)

National Cancer Institute to NOAH M HAHN

USD 656,816
2019 - 2024
Project list item
Defining the impact of intra-tumoral morphologic, immune and mutational heterogeneity in urothelial carcinoma

National Cancer Institute to HIKMAT AL-AHMADIE

USD 410,835
2019 - 2024
Project list item
The role of a new molecular driver in bladder cancer

National Cancer Institute to DALEY MORERA

USD 45,016
2018 - 2021
Project list item
Elucidating immunotherapy resistance mechanisms in non-T cell-inflamed bladder cancer

National Cancer Institute to RANDY F. SWEIS

USD 212,669
2018 - 2022
Project list item
Novel recombinant BCG for immunotherapy of bladder cancer

National Cancer Institute to BORIS SHOR

USD 290,014
2018 - 2019
Project list item
SPORE in Bladder Cancer

National Cancer Institute to DEAN F. BAJORIN, TIMOTHY AN-THY CHAN, IRINA OSTROVNAYA, HIKMAT AL-AHMADIE, MICHAEL STEPHEN GLICKMAN, DAVID B SOLIT

USD 2,299,837
2018 - 2023
Project list item
Modeling bladder cancer metastasis using human patient-derived tumor organoids

Bladder Cancer Advocacy Network to Michael M Shen

USD 300,000
2018 - 2020
Project list item
Unraveling disparate roles of Notch-1 and Notch-2 signaling in bladder cancer.

Michael Smith Foundation for Health Research to Peter C Black

USD 338,302
2018 - 2023
Project list item
Potentiation of Immunotherapy with targeted nanoporphyrin in bladder cancer

United States Department of Veterans Affairs to CHONG-XIAN PAN

 
2018 - 2022
Project list item
Role of B-arrestins in bladder cancer progression and response to chemotherapy

United States Department of Veterans Affairs to BAL L LOKESHWAR

 
2018 - 2022
load more...